The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
Antoine Angelergues
Honoraria - Sanofi
Denis Maillet
No relevant relationships to disclose
Aude Flechon
Honoraria - Astellas Pharma; Ferring; Janssen; Sanofi
Mustafa Ozguroglu
Consultant or Advisory Role - Astellas Pharma; Janssen; Sanofi
Florence Mercier
Consultant or Advisory Role - Boston Scientific; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Sanofi
Aline Guillot
No relevant relationships to disclose
Sylvestre Le Moulec
No relevant relationships to disclose
Gwenaelle Gravis
Consultant or Advisory Role - Sanofi (U)
Philippe Beuzeboc
Consultant or Advisory Role - Astellas Pharma; Ipsen; Janssen; Sanofi
Honoraria - Astellas Pharma; Ipsen; Janssen; Sanofi
Christophe Massard
Consultant or Advisory Role - Janssen; Sanofi
Honoraria - Janssen; Sanofi
Thibault De La Motte Rouge
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Astellas Pharma
Nicolas Delanoy
No relevant relationships to disclose
Reza-Thierry Elaidi
No relevant relationships to disclose
Stephane Oudard
Consultant or Advisory Role - Amgen; Bayer; Keocyt; Novartis; Roche; Sanofi
Honoraria - Amgen; Bayer; Keocyt; Novartis; Pfizer; Roche; Sanofi